Publications directory

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm

The web Directory of Information Materials for People Affected by Cancer is regularly updated and currently has details of over 1,900 booklets, leaflets, books and audiovisual materials for people affected by cancer. Most have been published in the last five years but we have included some older ones that are still useful.

Results: 21

Cover image of 'Newer antibodies against CD20'

Newer antibodies against CD20 (April 2020)

Lymphoma Action

Newer antibodies against CD20 are beginning to offer alternatives to rituximab for some people with lymphoma. This factsheet covers: antibodies targeting CD20; ofatumumab (Arzerra®); obinutuzumab (Gazyvaro®). It considers who can have these antibodies, how they are given, possible side effects.

Cover image of 'Rituximab for lymphoma'

Rituximab for lymphoma (February 2020)

Lymphoma Action

This factsheet is about the monoclonal antibody rituximab in the treatment of lymphoma. It tells you how rituximab works, who might be given it and what to expect during treatment. 

Cover image of 'Brentuximab vedotin'

Brentuximab vedotin (April 2020)

Lymphoma Action

Brentuximab vedotin is a targeted drug used in the treatment of certain types of lymphoma. This factsheets explains what it is, who can have it, how it is given, the benefits and possible side effects.

Cover image of 'Nivolumab (OPDIVO®)  [Polish]'

Nivolumab (OPDIVO®) [Polish] (January 2020)

Macmillan Cancer Support

Nivolumab (OPDIVO®) is a targeted therapy drug used to treat melanoma, non-small cell lung cancer or kidney (renal cell) cancer. 

Cover image of 'Ipilimumab [Polish]'

Ipilimumab [Polish] (January 2020)

Macmillan Cancer Support

Ipilimumab is a targeted therapy drug used to treat advanced melanoma. This describes how it works, how it is given, and some of the possible side-effects.

Cover image of 'Daratumumab (Darzalex®)'

Daratumumab (Darzalex®) (January 2019)

Myeloma UK

Daratumumab, also known as Darzalex®, is a monoclonal antibody drug used in the treatment of myeloma. This booklet describes what it is, how it works, how it is given, and the possible side-effects.

Cover image of 'Isatuximab'

Isatuximab (December 2019)

Myeloma UK

Isatuximab is a new drug that is being investigated for the treatment of myeloma. This factsheet describes briefly what it is, how it works, how it is given, the possible benefits over existing drugs, the possible side-effects, and its availability in the UK.

Cover image of 'Elotuzumab (Empliciti®)'

Elotuzumab (Empliciti®) (November 2019)

Myeloma UK

Elotuzumab is a new drug that is being investigated for the treatment of myeloma. This factsheet describes briefly what it is, how it works, how it is given, the possible benefits over existing drugs, the possible side-effects, its availability in the UK, and the future.

Cover image of 'Thalidomide'

Thalidomide (January 2019)

Myeloma UK

This treatment guide has information about thalidomide, a drug used in the treatment of myeloma. It explains  what it is, how it works, and how it is given, and describes the possible side-effects.

Cover image of 'Antibody therapy for lymphoma (including rituximab)'

Antibody therapy for lymphoma (including rituximab) (February 2019)

Lymphoma Action

This factsheet explains what antibody therapy is and how it is used to treat lymphoma.

Sorry, no publications found.
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm